Immunotherapy using the streptococcal preparation OK-432 for the treatment of uterine cervical cancer. Cervical Cancer Immunotherapy Study Group

Gynecol Oncol. 1989 Dec;35(3):367-72. doi: 10.1016/0090-8258(89)90081-4.


The efficacy of immunotherapy using a streptococcal preparation, OK-432, was evaluated in each clinical stage of uterine cervical cancer. The 382 eligible patients were stratified by clinical stage and presence/absence of surgery. Within each stratum, patient's were randomly allocated to OK-432 treatment or to control treatment. OK-432 significantly inhibited recurrence in patients with stage II cervical cancer; the recurrence-free interval and survival time were remarkably prolonged in patients with stage II disease who underwent surgery. However, OK-432 did not significantly prolong these parameters in patients with stage III disease. Retrospective analyses revealed that in patients with or without lymph node metastases who underwent surgery, the recurrence-free interval and survival time were significantly prolonged by OK-432 treatment. These results indicate that OK-432 is an effective and useful postoperative immunotherapeutic agent for uterine cervical cancer.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Biological Products / therapeutic use*
  • Female
  • Humans
  • Immunotherapy / methods*
  • Picibanil / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Recurrence
  • Retrospective Studies
  • Uterine Cervical Neoplasms / epidemiology
  • Uterine Cervical Neoplasms / mortality
  • Uterine Cervical Neoplasms / therapy*


  • Biological Products
  • Picibanil